Evaluation of the effectiveness of low-dose topical citrate anticoagulation used in plasma exchange: a single-center randomized controlled trial

The Application of New Locally Controllable Sodium Citrate Anticoagulation Technology in Plasma Exchange

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087862

Enrollment

Unknown

Registered

2024-08-06

Start date

2022-07-13

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All diseases requiring plasma exchange

Interventions

Experimental group:Low-dose local citrate anticoagulation

Comparison Group:Low molecular weight heparin or heparin free anticoagulation

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) 18 years of age = age. (2) Plasma replacement therapy = 3 times. (3) Complete clinical profile. (4) No contraindications to sodium citrate anticoagulation. (5) Informed consent.

Exclusion criteria

Exclusion criteria: (1) The patient has poor vascular access flow and frequent alarms. (2) Patient is agitated and unable to cooperate with treatment. (3) Severe allergy to plasma, sodium citrate, etc. (4) Systemic circulatory failure that is difficult to correct with drugs. (5) Blood lactate greater than 4 mmol/L. (6) Severe hypernatremia (blood sodium > 160 mmol/L). (7) Hepatic failure. (8) Loss of compensatory metabolic alkalosis.

Design outcomes

Primary

Measure	Time frame
Coagulation indicators;Incidence of extracorporeal circulation blockage;	—

Secondary

Measure	Time frame
Incidence of complications;	—

Countries

China

Contacts

Public ContactRuizhao Li

Guangdong Provincial People's Hospital

375570703@qq.com+86 137 1103 9840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026